FALL 2025

 We’re Starting Our Second Round of Patient Testing

Hello all, this is Neal Weinstock, CEO of Soliddd, chiming in personally (the entire newsletter is usually the work of Soliddd's marketing director, Mike Silbergleid). I’ve spoken personally with so many of you, and I’ve seen many of the emails you have written to us, so that I feel we’re all in this together. I want to thank you personally for your support on this journey that we have been on for 15 years now. And now that our team is making so much progress on getting our science into a product that I hope many of you will actually be able to wear and benefit from in several months… that is truly exciting.

Keep reading for more. Over to you, Mike…

And the news many of you have been waiting for...

We’re ready to begin our next round of patient testing at Soliddd. We have created a number of binocular headsets that allow us to run much more sophisticated tests than we had available last year (when we tested a significant number of people with macular degeneration and Stargardt disease).

This time, we are particularly interested in testing people with loss of vision in some portion of their field, including those with

• Central cone dystrophy
• Cone rod dystrophy
• Glaucoma
• Macular degeneration and Stargardt disease, as before. Now, however, not only for central area vision loss, as we tested last year, but also for geographic atrophy.
• NAION
• Optic neuritis
• Retinal tears, blastomas, and other issues that block some portion of the visual field.
• Stroke
• And other retinopathy

We will start this new round of testing in New York City and gradually roll testing out to other locations. We are grateful for all of you who have told us you want to be involved!

To be considered for the program, please sign up here.

In Other News...

• We have begun the process of volume manufacturing.
• We are creating several prototype units that will be ready early in 2026. These will look and feel much like our final product next year, but they are based on the development kit board version of the processor we use, which doesn’t fit into the eyeglasses frame we’ll use in the final product. So, the processing unit sits outside the glasses in a little box. (Don’t worry! In the final product, everything will be built into the glasses frame!)
• We’ve welcomed two new full-time software engineers to our team since our last newsletter.
• What we now think of as our most important patent has been issued in the United States. (For those of you interested, the patent number is 12452550 entitled “Multi-tiled plenoptic system for the detection and correction of ocular defects and for improved foveated rendering.”) And we have applied for patents on the same invention in many other countries.
• Next month, we’ll be at CES in Las Vegas and at SPIE Photonics West in San Francisco. We won’t be exhibiting, but we will offer private demos. If you want to meet, write us.